Published online Aug 16, 2023. doi: 10.12998/wjcc.v11.i23.5525
Peer-review started: March 19, 2023
First decision: June 15, 2023
Revised: June 23, 2023
Accepted: July 19, 2023
Article in press: July 19, 2023
Published online: August 16, 2023
Processing time: 149 Days and 16.7 Hours
Rezūm™ water vapor therapy is a new minimally invasive endoscopic technology for the management and treatment of benign prostatic hyperplasia.
A 63-year-old male presented to our department with severe dysuria, frequency, urgency, and interrupted stream 2 mo after receiving Rezūm™ therapy. The symptoms were caused by a retained floating emphysematous necrotic sloughed tissue. We also discovered a persistent bacterial infection that was resistant to parenteral antimicrobial therapy. The treatment of the patient included surgical removal of the necrotic tissue.
Despite the good safety profile and minimal adverse events related to Rezūm™ therapy, major complications can still occur.
Core Tip: The current report describes a new finding with infected emphysematous sloughed tissue ball after Rezum therapy that is secondary to gas forming organism. It predisposed the patient post operatively to frequent urine retention and severe lower urinary tract symptoms that is refractory to antimicrobial therapy that was managed successfully by endoscopic removal.